Dianthus Therapeutics Completes Phase 2 Enrollment for Myasthenia Gravis Trial
Dianthus Therapeutics has completed enrollment for its Phase 2 trial of DNTH103 for Generalized Myasthenia Gravis, with top-line results expected in September.
2 minutes to read